Evidence map›Paper›PMID 31862745›Full record

GuidelineDiabetes care2020

2. Classification and Diagnosis of Diabetes:

American Diabetes Association

5 registry-linked trialsAbstract readHistorical ArticlePractice GuidelineReview
PubMed Publisher
In one paragraph

Guideline in Diabetes care, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT02437084. Cited by 1,695 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1,695citing papers in PubMed, 11 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02437084 phase4completed

Relationship Between Insulin Resistance and Statin Induced Type 2 Diabetes, and Integrative Personal Omics Profiling

Ran2015Enrolled115Registered outcomes6Posted comparisons6ConditionsHyperlipidemia, Insulin Resistance, Type 2 DiabetesArmsAtorvastatin
PMID 22883507PMID 23219296PMID 25262344PMID 18551118PMID 25754552PMID 27614854PMID 24326527PMID 25634843PMID 9177392PMID 10491414PMID 16046313PMID 22424236other papers from this trial
Open the trial in the graph
NCT04841096 phase3completedstarted 2023, after this paper: background citation

Efficacy and Safety of the Oral Combined Therapy Glimepiride / Vildagliptin / Metformin in Patients With Type 2 Diabetes With Dual Treatment Failure

Ran2023Enrolled162Registered outcomes5Posted comparisons0ConditionsType 2 DiabetesArmsA1=Glimepiride / Vildagliptin / Metformin (1 mg/ 50 mg/ 500 mg), (A2) Glimepiride/Vildagliptin/Metformin, (B2) Glimepiride/Vildagliptin/Metformin, B2=Glimepiride / Vildagliptin / Metformin (1 mg/ 50 mg/ 500 mg)
PMID 9585393PMID 32022600PMID 27088241PMID 24199686PMID 22246944PMID 30072404PMID 15111553PMID 15850551PMID 26519337PMID 26775266PMID 28155046PMID 29405543other papers from this trial
Open the trial in the graph
NCT04606576 phase3terminatednot on this map

A Double-Blinded, Placebo-controlled, Double Dummy, Multi-center Randomized, Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With T2DM With Inadequate Glycemic Control on 1, 2 or 3 Oral Glucose-lowering Agents.

TypeinterventionalSponsorOramed, Ltd.Ran2020 to 2023Enrolled710ConditionsType 2 Diabetes MellitusArmsPlacebo, ORMD-0801 QD, ORMD-0801 BD
NCT05349227 narecruitingnot on this mapstarted 2022, after this paper: background citation

Comprehensive Outcomes for After Cancer Health (COACH): the Feasibility and Impact of an MHealth Augmented Coaching Program for Self-Management in Cancer Survivors

TypeinterventionalSponsorPack HealthRan2022 to 2027Enrolled625ConditionsOvarian Cancer, Breast Cancer, Lung Cancer, Gastric CancerArmsDigital Health Coaching Program, Fitbit
NCT05592288 nacompletednot on this mapstarted 2024, after this paper: background citation

The Impact of a Mobile Application Designed for Adults at Risk of Developing Diabetes on Following the Mediterranean Diet Plan, Physical Activity and Metabolic Parameters: a Study Protocol for a Randomized Controlled Trial

TypeinterventionalSponsorAkdeniz UniversityRan2024 to 2024Enrolled61ConditionsDiabetes Mellitus Risk, PreDiabetesArmsPREDIABE-TR mobile app.
3 · Its place in the literature

Who cites it

1,695 citing papers in PubMed, 11 syntheses or guidelines pooled it.

  1. Treatment Options for Patients with Maturity-Onset Diabetes of the Young (MODY): A Systematic Review of Literature: 2026 Update.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Guideline
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

1,635 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

American Diabetes Association

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The American Diabetes Association (ADA) "Standards of Medical Care in Diabetes" includes the ADA's current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care. Members of the ADA Professional Practice Committee (https://doi.org/10.2337/dc20-SPPC), a multidisciplinary expert committee, are responsible for updating the Standards of Care annually, or more frequently as warranted. For a detailed description of ADA standards, statements, and reports, as well as the evidence-grading system for ADA's clinical practice recommendations, please refer to the Standards of Care Introduction (https://doi.org/10.2337/dc20-SINT). Readers who wish to comment on the Standards of Care are invited to do so at professional.diabetes.org/SOC.

Indexed as

Diabetes MellitusEndocrinologyHistory, 21st CenturyHumansReference StandardsSocieties, MedicalStandard of CareUnited States

Identifiers

PMID31862745

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.